Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.04.20.590412

Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies

Abstract

BackgroundAmyloid-beta (A{beta})-directed antibodies tested clinically for therapeutic activity against Alzheimers disease (AD) have shown varying degrees of efficacy. Although all of these antibodies target the A{beta} peptide, their binding profile to different molecular species of A{beta} differs and may underlie the observed variability in clinical outcomes. ObjectiveExplore the relationship between targeting of soluble toxic A{beta} species and therapeutic efficacy. MethodsSurface plasmon resonance (SPR) was used to conduct a side-by-side comparison of the binding of various A{beta}-directed antibodies to monomers and soluble A{beta} oligomers from AD brains. Immunohistochemistry was performed to assess reactivity with plaque. Preclinical activity was assessed in human amyloid precursor protein (APP) transgenic mouse models of AD. ResultsNon-selective, pan-A{beta} reactive antibodies such as crenezumab and gantenerumab, which have failed to produce a clinical benefit, bound all forms of A{beta} tested. In a competition assay, these antibodies lost the ability to bind toxic AD brain oligomers when exposed to monomers. Aggregate-selective antibodies such as aducanumab, lecanemab and donanemab, showed reduced monomer binding and a greater ability to withstand monomer competition which correlated with their reported inhibition of cognitive decline. Of the antibodies in earlier stages of clinical testing, ACU193 and PMN310 displayed the greatest ability to retain binding to toxic AD brain oligomers while PRX h2731 was highly susceptible to monomer competition. Plaque binding was observed with all aggregate-reactive antibodies with the exception of PMN310, which was strictly selective for soluble oligomers. Targeting of oligomers by PMN310 protected cognition and was not associated with microhemorrhages in mouse models of AD. ConclusionsOverall, these results suggest that selectivity for soluble toxic A{beta} oligomers may be a driver of clinical efficacy, with a potentially reduced risk of ARIA if engagement with plaque is minimized.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kaplan, J. M., Gibbs, E., Coutts, J., Zhao, B., Mackenzie, I., Cashman, N. R.. 2024-04-25. Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies. https://doi.org/10.1101/2024.04.20.590412

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

E2F4 gene therapy reverses established synaptic and cognitive deficits and remodels learning-associated signaling in Alzheimer's disease mice

Alzheimer's disease (AD) causes progressive synaptic dysfunction, neurodegeneration, and cognitive decline, yet strategies capable of reversing established deficits remain limited. Here, we show that neuronal expression of a p38MAPK phosphorylation-resistant human E2F4 variant (hE2F4DN), delivered by adeno-associated virus, restores hippocampal long-term potentiation and memory in homozygous 5xFAD mice after functional impairment is established. Treatment also reduces amyloid-{beta} and phospho-tau pathology and prevents hippocampal neuronal loss. Integrated proteomic and phosphoproteomic analyses reveal remodeling of metabolic, redox, neuroimmune, synaptic-vesicle, and GSK3{beta}-associated signaling pathways. Following contextual fear conditioning, hE2F4DN-treated mice exhibit broader learning-associated synaptic proteomic signatures and distinct phosphoregulatory responses involving synaptic machinery. These findings demonstrate that E2F4 gene therapy can reverse established synaptic and cognitive deficits while preserving neuronal integrity and reshaping molecular responses to learning, identifying E2F4 phosphorylation as a potential therapeutic target for advanced AD states.

neuroscience↗

Complex Spatial and Temporal Organization of Functional Brain Networks

Recent research exploring brain-behavior associations has relied on the language of complex systems to understand how stable behavioral individual differences emerge from brain function. At the same time, advances in neuroimaging have provided greater insight into both the topological and temporal properties of macroscale cortical networks. These new approaches offer a potential avenue for understanding how functional activity in the brain might behave in a manner that aligns with complex-systems interpretations of psychological traits. The present study used resting-state data from the Human Connectome project (N = 994) to explore associations between the spatial and temporal features of functional brain networks. Using an adaptive frequency approach to explore brain function at different timescales together with a family of methods from complex systems theory, we identified patterns of brain state organization reflecting a state-trait continuum, with more stable trait-like dynamics and greater functional coupling between networks in lower frequency oscillations. Additionally, we found evidence of greater coupling across timescales in brain networks associated with higher-order cognition. This research supports interpretations of brain organization as a spatiotemporal hierarchy and provides future avenues for exploring brain-behavior associations from a complex system perspective.

neuroscience↗

A Mechanistic Account of Dedifferentiation in the Aging Visual System

To uncover the mechanisms of age-related dedifferentiation, we simulated neural degradation in a computational model of the ventral visual stream. Severing connections or adding noise, whether in inferotemporal cortex (IT) or upstream, reduced IT differentiation, indicating that dedifferentiation need not originate locally. Degrading peripheral V1, which preferentially drove place-selective IT neurons, selectively reduced place differentiation, a candidate mechanism for the stronger place dedifferentiation reported in aging.

neuroscience↗